- testing |
| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 14 Nov 2025 | 8 Nov 2025 |
| Max Healthcare Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve unaudited standalone and consolidated financial results of the Company for the quarter and half year ended September 30 2025 Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2025 (As per BSE Announcement dated on: 14.11.2025) | ||
| Board Meeting | 13 Aug 2025 | 6 Aug 2025 |
| Max Healthcare Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 inter alia to consider and approve unaudited standalone and consolidated financial results of the Company for the quarter ended June 30 2025. Standalone and Consolidated Financial Results for the quarter ended June 30, 2025 (As Per BSE Announcement Dated on: 13.08.2025) | ||
| Board Meeting | 11 Jul 2025 | 11 Jul 2025 |
| Disclosure under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 | ||
| Board Meeting | 20 May 2025 | 13 May 2025 |
| Max Healthcare Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2025 inter alia to consider and approve Financial Results and recommend Final Dividend if any Outcome of Board Meeting held on May 20, 2025 Appointment of Statutory Auditor (As Per BSE Announcement Dated on: 20/05/2025) | ||
| Board Meeting | 21 Mar 2025 | 22 Mar 2025 |
| Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 | ||
| Board Meeting | 12 Mar 2025 | 12 Mar 2025 |
| Outcome of Board Meeting | ||
| Board Meeting | 30 Jan 2025 | 24 Jan 2025 |
| Max Healthcare Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2025 inter alia to consider and approve unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended December 31 2024. Infusion of funds in Jaypee Healthcare Limited Agreement to lease for setting up ~500 bedded build-to-suit hospital at Thane, Maharashtra (As per BSE Announcement Dated on 30/01/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.